No drug interactions with dupilumab have been identified to date. Patients receiving dupilumab are considered immunosuppressed and should not receive live vaccines due to the risk for infection. Non-live (killed) vaccines may be administered and have been found to produce appropriate seroconversion rates.[2]
Pediatr Pharm. 2019;25(6) © 2019 University of Virginia
processing....
Topical Ruxolitinib Quickly Relieves Atopic Dermatitis Itch in Black Patients
Perioral Dermatitis
Exfoliative Dermatitis
Seborrheic Dermatitis
Topical Ruxolitinib Quickly Relieves Atopic Dermatitis Itch in Black Patients
Dermatologists Share Vitiligo Breakthrough News With Patients
The Pediatric Landscape in Moderate to Severe Atopic Dermatitis: What Do New Data and Approvals Mean for Practice?
0.5 CME Credits
Topical Roflumilast Approved for Psoriasis in Adults and Adolescents
